3-(2-bromo-ethoxy)-2-(4-[2-butynyloxy]-benzene-sulfonyl-amino)propionic acid methyl ester | 287408-01-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(2-bromo-ethoxy)-2-(4-[2-butynyloxy]-benzene-sulfonyl-amino)propionic acid methyl ester
• 英文别名: 3-(2-Bromo-ethoxy)-2-(4-[2-butynyloxy]-benzene-sulfonylamino)propionic acid methyl ester；methyl 3-(2-bromoethoxy)-2-[(4-but-2-ynoxyphenyl)sulfonylamino]propanoate
• CAS: 287408-01-9
• 化学式: C₁₆H₂₀BrNO₆S
• 分子量: 434.308
• InChiKey: NEJAILDEHMAFNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  99.3
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-(2-bromo-ethoxy)-2-(4-[2-butynyloxy]-benzene-sulfonyl-amino)propionic acid methyl ester 在 potassium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 1.0h， 以73.8%的产率得到4-([4-(2-butynyloxy)phenyl]sulfonyl}-morpholine-3-carboxylic acid,methyl ester
  参考文献：
  名称：

  ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS

  摘要：

  公开号：

  EP1144368B1
• 作为产物：
  描述：

  methyl 2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-3-hydroxypropanoate 在 三氟化硼乙醚 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 生成 3-(2-bromo-ethoxy)-2-(4-[2-butynyloxy]-benzene-sulfonyl-amino)propionic acid methyl ester
  参考文献：
  名称：

  Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates

  摘要：

  The SAR of a series of potent sulfonamide hydroxamate TACE inhibitors bearing a butynyloxy P1' group was explored. In particular, compound 5k has excellent in vitro potency against TACE enzyme and in cells, and oral activity in an in vivo model of TNF-alpha production and a collagen-induced arthritis model.

  DOI：

  10.1016/j.bmcl.2005.06.072

文献信息

• Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors
  申请人：——

  公开号：US20030008849A1

  公开（公告）日：2003-01-09

  Compounds of the formula: 1 are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  公式为1的化合物可用于治疗由TNF-&agr;介导的疾病条件，例如类风湿性关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和退行性软骨丢失。
• Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors
  申请人：Levin I. Jeremy

  公开号：US20050113346A1

  公开（公告）日：2005-05-26

  Compounds of the formula: are useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  式为的化合物在治疗由TNF-α介导的疾病条件方面非常有用，例如类风湿性关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和退行性软骨损失。
• Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
  申请人：Hofmeister Armin

  公开号：US20050009864A1

  公开（公告）日：2005-01-13

  The invention relates to compounds of the formula I in which R1 to R9 are as defined herein. In one embodiment, these compounds may be used as antihypertensives, for reducing or preventing ischemia-induced damage, as medicaments for surgical intervention for the treatment of ischemias of the nervous system, of stroke and of cerebral edema, of shock, of impaired respiratory drive, for the treatment of snoring, as laxative, as agent against ectoparasites, to prevent the formation of gallstones, as antiatherosclerotics, agents against late complications of diabetes, cancers, fibrotic disorders, endothelial dysfunction, organ hypertrophies and hyperplasias. In one embodiment, the compounds may be inhibitors of the cellular sodium-proton antiporter and influence serum lipoproteins and thus be used for the prophylaxis and for the regression of atherosclerotic lesions.

  本发明涉及公式I中R1至R9所定义的化合物。在一种实施例中，这些化合物可用作降压药、用于减少或预防缺血引起的损伤、作为治疗神经系统缺血、中风和脑水肿、休克、呼吸驱动力受损、打鼾的药物、作为泻药、对抗外寄生虫的药物、预防胆石形成、作为抗动脉粥样硬化药物、对抗糖尿病晚期并发症、癌症、纤维化疾病、内皮功能障碍、器官肥大和增生的药物。在一种实施例中，这些化合物可以是细胞钠-质子抗转运体的抑制剂，影响血清脂蛋白，因此可用于动脉粥样硬化病变的预防和回归。
• Acetylenic &agr;-amino acid-based sulfonamide hydroxamic acid tace inhibitors
  申请人：American Cyanamid Company

  公开号：US06225311B1

  公开（公告）日：2001-05-01

  Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  分子式为的化合物在治疗由TNF-α介导的疾病条件方面非常有用，例如类风湿性关节炎，骨关节炎，败血症，艾滋病，溃疡性结肠炎，多发性硬化症，克罗恩病和退行性软骨丢失。
• US6225311B1
  申请人：——

  公开号：US6225311B1

  公开（公告）日：2001-05-01